SK3412000A3 - Method of increasing bone volume using non-naturally-occurring fp selective agonists - Google Patents

Method of increasing bone volume using non-naturally-occurring fp selective agonists Download PDF

Info

Publication number: SK3412000A3
Authority: SK; Slovakia
Prior art keywords: naturally occurring; use according; agonist; bone; selective
Prior art date: 1997-09-09

Application number

SK341-2000A

Other languages

English (en)

Slovak (sk)

Inventor

James Richard Hartke

Mark Walden Lundy

Mitchell Anthony Delong

Original Assignee

Procter & Gamble

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-09

Filing date

1998-09-04

Publication date

2000-12-11

1998-09-04 Application filed by Procter & Gamble filed Critical Procter & Gamble

2000-12-11 Publication of SK3412000A3 publication Critical patent/SK3412000A3/sk

Links

210000000988 bone and bone Anatomy 0.000 title claims abstract description 65
239000000556 agonist Substances 0.000 title claims abstract description 52
230000001965 increasing effect Effects 0.000 title claims abstract description 20
238000000034 method Methods 0.000 title abstract description 23
208000020084 Bone disease Diseases 0.000 claims abstract description 14
150000003180 prostaglandins Chemical class 0.000 claims description 21
102000005962 receptors Human genes 0.000 claims description 16
108020003175 receptors Proteins 0.000 claims description 16
208000001132 Osteoporosis Diseases 0.000 claims description 14
102000000471 Prostaglandin F receptors Human genes 0.000 claims description 14
108050008995 Prostaglandin F receptors Proteins 0.000 claims description 14
230000002787 reinforcement Effects 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 10
WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical group C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 claims description 10
229950009951 fluprostenol Drugs 0.000 claims description 10
-1 3-chlorophenoxy Chemical group 0.000 claims description 7
102000015433 Prostaglandin Receptors Human genes 0.000 claims description 7
108010050183 Prostaglandin Receptors Proteins 0.000 claims description 7
230000002964 excitative effect Effects 0.000 claims description 6
208000010392 Bone Fractures Diseases 0.000 claims description 5
102000017953 prostanoid receptors Human genes 0.000 claims description 5
108050007059 prostanoid receptors Proteins 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical group C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 claims description 3
208000010191 Osteitis Deformans Diseases 0.000 claims description 3
208000027868 Paget disease Diseases 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
229960004409 cloprostenol Drugs 0.000 claims description 3
208000027202 mammary Paget disease Diseases 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 claims description 2
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 2
FYBFDIIAPRHIQS-KKBLUXBBSA-N (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-thiophen-3-yloxybut-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC=1C=CSC=1 FYBFDIIAPRHIQS-KKBLUXBBSA-N 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
229950004900 alfaprostol Drugs 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
229950007806 delprostenate Drugs 0.000 claims description 2
125000004404 heteroalkyl group Chemical group 0.000 claims description 2
125000001072 heteroaryl group Chemical group 0.000 claims description 2
229960001160 latanoprost Drugs 0.000 claims description 2
GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
230000007774 longterm Effects 0.000 claims description 2
FNAMRDZHKYQEBA-YDQNNXAVSA-N methyl (2e,5z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hepta-2,5-dienoate Chemical compound COC(=O)\C=C\C\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(Cl)=C1 FNAMRDZHKYQEBA-YDQNNXAVSA-N 0.000 claims description 2
OZDSQCVLNUIYLN-JNAAKWLTSA-N methyl (z)-7-[(1r,2s,3r,5s)-2-[(3s)-5-cyclohexyl-3-hydroxypent-1-ynyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound COC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1C#C[C@@H](O)CCC1CCCCC1 OZDSQCVLNUIYLN-JNAAKWLTSA-N 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
150000003536 tetrazoles Chemical class 0.000 claims description 2
229950002099 tiaprost Drugs 0.000 claims description 2
230000004060 metabolic process Effects 0.000 claims 1
210000002307 prostate Anatomy 0.000 claims 1
229910052727 yttrium Inorganic materials 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 13
150000001875 compounds Chemical class 0.000 description 19
230000000694 effects Effects 0.000 description 13
239000000203 mixture Substances 0.000 description 11
230000002035 prolonged effect Effects 0.000 description 9
229940094443 oxytocics prostaglandins Drugs 0.000 description 8
238000003556 assay Methods 0.000 description 7
239000003937 drug carrier Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 5
239000003883 ointment base Substances 0.000 description 5
238000007910 systemic administration Methods 0.000 description 5
206010017076 Fracture Diseases 0.000 description 4
230000001195 anabolic effect Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000011164 ossification Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
208000006386 Bone Resorption Diseases 0.000 description 3
206010065687 Bone loss Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000024279 bone resorption Effects 0.000 description 3
230000008416 bone turnover Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
230000016160 smooth muscle contraction Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
101150058615 Ptger1 gene Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
230000008602 contraction Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
238000009499 grossing Methods 0.000 description 2
102000046038 human SDHA Human genes 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000008439 repair process Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000018035 Dental disease Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000282339 Mustela Species 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
235000019484 Rapeseed oil Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000014151 Stomatognathic disease Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010046798 Uterine leiomyoma Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000002617 bone density conservation agent Substances 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
230000010072 bone remodeling Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000013170 computed tomography imaging Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
208000021863 corticosteroid-induced osteoporosis Diseases 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000001582 osteoblastic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
108091014625 prostaglandin binding proteins Proteins 0.000 description 1
229940127293 prostanoid Drugs 0.000 description 1
150000003814 prostanoids Chemical class 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003351 stiffener Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK341-2000A 1997-09-09 1998-09-04 Method of increasing bone volume using non-naturally-occurring fp selective agonists SK3412000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5830697P	1997-09-09	1997-09-09
PCT/US1998/018338 WO1999012551A1 (en)	1997-09-09	1998-09-04	Method of increasing bone volume using non-naturally-occurring fp selective agonists

Publications (1)

Publication Number	Publication Date
SK3412000A3 true SK3412000A3 (en)	2000-12-11

Family

ID=22015996

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK341-2000A SK3412000A3 (en)	1997-09-09	1998-09-04	Method of increasing bone volume using non-naturally-occurring fp selective agonists

Country Status (20)

Country	Link
US (1)	US6156799A (tr)
EP (1)	EP1045694A1 (tr)
JP (1)	JP2001515864A (tr)
KR (1)	KR20010023840A (tr)
CN (1)	CN1269721A (tr)
AR (1)	AR013479A1 (tr)
AU (1)	AU739275B2 (tr)
BR (1)	BR9811780A (tr)
CA (1)	CA2303800A1 (tr)
CO (1)	CO4980882A1 (tr)
HU (1)	HUP0004581A2 (tr)
ID (1)	ID24827A (tr)
IL (1)	IL134760A0 (tr)
NO (1)	NO20001171L (tr)
PE (1)	PE119099A1 (tr)
PL (1)	PL339288A1 (tr)
SK (1)	SK3412000A3 (tr)
TR (1)	TR200000662T2 (tr)
WO (1)	WO1999012551A1 (tr)
ZA (1)	ZA988228B (tr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3711900A (en) *	1999-03-05	2000-09-21	Procter & Gamble Company, The	Method of increasing bone volume using non-naturally-occurring ep1 selective agonists
WO2000051616A1 (en) *	1999-03-05	2000-09-08	The Procter & Gamble Company	Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
IL145122A0 (en) *	1999-03-05	2002-06-30	Procter & Gamble	C16 unsaturated fp-selective prostaglandin analogs
JP2002538138A (ja) *	1999-03-05	2002-11-12	ザプロクターアンドギャンブルカンパニー	Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
CA2303060A1 (en) *	1999-04-14	2000-10-14	United States Gear Corporation	Towed vehicle brake controller
US6894175B1 (en)	1999-08-04	2005-05-17	The Procter & Gamble Company	2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en)	2000-03-31	2002-03-28	Delong Mitchell Anthony	Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US7467892B2 (en)	2000-08-29	2008-12-23	Imaging Therapeutics, Inc.	Calibration devices and methods of use thereof
AU2001286892B2 (en)	2000-08-29	2007-03-15	Imaging Therapeutics Inc.	Methods and devices for quantitative analysis of x-ray images
US6904123B2 (en)	2000-08-29	2005-06-07	Imaging Therapeutics, Inc.	Methods and devices for quantitative analysis of x-ray images
US8639009B2 (en)	2000-10-11	2014-01-28	Imatx, Inc.	Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
US7660453B2 (en)	2000-10-11	2010-02-09	Imaging Therapeutics, Inc.	Methods and devices for analysis of x-ray images
CA2446296A1 (en)	2001-05-25	2002-12-05	Imaging Therapeutics, Inc.	Methods to diagnose treat and prevent bone loss
ES2360604T3 (es) *	2001-07-23	2011-06-07	Ono Pharmaceutical Co., Ltd.	Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4.
KR20070043059A (ko) *	2001-07-23	2007-04-24	오노 야꾸힝 고교 가부시키가이샤	Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하 질환의치료제
US20060013851A1 (en) *	2002-02-07	2006-01-19	Giroux Karen J	Therapeutic polyanhydride compounds for drug delivery
US8965075B2 (en)	2002-09-16	2015-02-24	Imatx, Inc.	System and method for predicting future fractures
US7840247B2 (en)	2002-09-16	2010-11-23	Imatx, Inc.	Methods of predicting musculoskeletal disease
US8600124B2 (en)	2004-09-16	2013-12-03	Imatx, Inc.	System and method of predicting future fractures
CA2519187A1 (en)	2003-03-25	2004-10-14	Imaging Therapeutics, Inc.	Methods for the compensation of imaging technique in the processing of radiographic images
EP1663002A4 (en) *	2003-09-19	2007-11-28	Imaging Therapeutics Inc	BONE STRUCTURE PROGNOSTIC METHOD AND SIMULATED BONE REMODELING
US20080058613A1 (en) *	2003-09-19	2008-03-06	Imaging Therapeutics, Inc.	Method and System for Providing Fracture/No Fracture Classification
US8290564B2 (en)	2003-09-19	2012-10-16	Imatx, Inc.	Method for bone structure prognosis and simulated bone remodeling
US8939917B2 (en)	2009-02-13	2015-01-27	Imatx, Inc.	Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4621100A (en) *	1981-09-25	1986-11-04	The Upjohn Company	Treatment of osteoporosis with prostaglandins
WO1993015767A1 (en) *	1992-02-05	1993-08-19	Merck & Co., Inc.	Implant therapy for bone growth stimulation
US5310759A (en) *	1992-08-12	1994-05-10	Bockman Richard S	Methods of protecting and preserving connective and support tissues
US5409911A (en) *	1992-09-11	1995-04-25	Merck & Co., Inc.	Prostaglandin analog for treating osteoporosis
US5747660A (en) *	1995-11-06	1998-05-05	The University Of Colorado	Nucleic acid encoding prostaglandin F2α receptor regulatory protein
US5703108A (en) *	1996-02-28	1997-12-30	Pfizer Inc.	Bone deposition by certain prostaglandin agonists

1998
- 1998-09-04 TR TR2000/00662T patent/TR200000662T2/tr unknown
- 1998-09-04 HU HU0004581A patent/HUP0004581A2/hu unknown
- 1998-09-04 AU AU92192/98A patent/AU739275B2/en not_active Ceased
- 1998-09-04 SK SK341-2000A patent/SK3412000A3/sk unknown
- 1998-09-04 KR KR1020007002516A patent/KR20010023840A/ko not_active Application Discontinuation
- 1998-09-04 WO PCT/US1998/018338 patent/WO1999012551A1/en not_active Application Discontinuation
- 1998-09-04 CN CN98808885A patent/CN1269721A/zh active Pending
- 1998-09-04 IL IL13476098A patent/IL134760A0/xx unknown
- 1998-09-04 ID IDW20000637A patent/ID24827A/id unknown
- 1998-09-04 BR BR9811780-7A patent/BR9811780A/pt not_active IP Right Cessation
- 1998-09-04 JP JP2000510448A patent/JP2001515864A/ja not_active Withdrawn
- 1998-09-04 CA CA002303800A patent/CA2303800A1/en not_active Abandoned
- 1998-09-04 US US09/148,105 patent/US6156799A/en not_active Expired - Fee Related
- 1998-09-04 PL PL98339288A patent/PL339288A1/xx unknown
- 1998-09-04 EP EP98944718A patent/EP1045694A1/en not_active Withdrawn
- 1998-09-08 AR ARP980104483A patent/AR013479A1/es unknown
- 1998-09-09 PE PE1998000854A patent/PE119099A1/es not_active Application Discontinuation
- 1998-09-09 CO CO98051811A patent/CO4980882A1/es unknown
- 1998-09-09 ZA ZA988228A patent/ZA988228B/xx unknown
2000
- 2000-03-07 NO NO20001171A patent/NO20001171L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20010023840A (ko)	2001-03-26
EP1045694A1 (en)	2000-10-25
NO20001171L (no)	2000-05-09
US6156799A (en)	2000-12-05
JP2001515864A (ja)	2001-09-25
TR200000662T2 (tr)	2000-07-21
CO4980882A1 (es)	2000-11-27
ZA988228B (en)	1999-03-09
IL134760A0 (en)	2001-04-30
WO1999012551A1 (en)	1999-03-18
BR9811780A (pt)	2000-09-12
ID24827A (id)	2000-08-24
AU9219298A (en)	1999-03-29
AR013479A1 (es)	2000-12-27
AU739275B2 (en)	2001-10-11
HUP0004581A2 (hu)	2001-05-28
PE119099A1 (es)	2000-02-03
NO20001171D0 (no)	2000-03-07
CN1269721A (zh)	2000-10-11
PL339288A1 (en)	2000-12-04
CA2303800A1 (en)	1999-03-18

Publication	Publication Date	Title
SK3412000A3 (en)	2000-12-11	Method of increasing bone volume using non-naturally-occurring fp selective agonists
TW518222B (en)	2003-01-21	Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
KR20090024281A (ko)	2009-03-06	다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
US6051563A (en)	2000-04-18	Methods for the administration of amifostine and related compounds
JPWO2003007991A1 (ja)	2004-11-04	Ｌｐａ受容体調節剤からなる膵液分泌制御剤
US20230364118A1 (en)	2023-11-16	Ribitol treatment
SK3402000A3 (en)	2000-12-11	Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject
EP2723348B1 (en)	2019-08-14	Method for treating obesity
Koylan et al.	2004	Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS)
US7238718B2 (en)	2007-07-03	Method for treating myolytic disease and method for screening antimyolytic agent
SK19332001A3 (sk)	2002-12-03	Použitie antagonistov kortizolu v liečení srdcového zlyhania
EP1158969A2 (en)	2001-12-05	Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
CZ2000808A3 (cs)	2000-06-14	Použití selektivního FP agonisty, který se přirozeně nevyskytuje
KR101059330B1 (ko)	2011-08-24	3,７디아자비시클로〔３,３,１〕노난 화합물을 포함하는 액상의 약제학적 제제 및 부정맥발작에 관련한 치료방법
JP2005514400A (ja)	2005-05-19	骨疾患の治療方法
WO2000051616A1 (en)	2000-09-08	Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
MXPA00002395A (en)	2001-12-04	Method of increasing bone volume
SK8572003A3 (en)	2004-07-07	Histamine receptor antagonists
Burk et al.	2007	Bimatoprost, a novel efficacious ocular hypotensive drug now recognized as a member of a new class of agents called prostamides
AU721955B2 (en)	2000-07-20	Verapamil as a medicament for the treatment of angina
MXPA00002394A (en)	2001-12-13	Method of increasing bone volume using non-naturally-occurring fp selective agonists
CZ20014406A3 (cs)	2002-04-17	Farmaceutický prostředek
JP2002538122A (ja)	2002-11-12	天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法